successful treatment of intracranial hemorrhage with recombinant activated factor vii in a patient with newly diagnosed acute myeloid leukemia: a case report and review of the literature

Clicks: 227
ID: 198150
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Intracranial hemorrhage (ICH) is a common complication in acute myeloid leukemia (AML) patients with an incidence rate of 6.3% [1]. Bleeding disorders related to disseminated intravascular coagulation (DIC) are common complications in AML cases [2]. Recombinant activated Factor VII (rFVIIa [NovoSeven®]) is approved for the treatment of bleeding complications with FVIII or FIX inhibitors in patients with congenital FVII deficiency. Use of rFVIIa for the treatment of acute hemorrhage in patients without hemophilia has been successful [3,4]. Herein, we describe the successful use of rFVIIa in a patient with acute ICH in the setting of newly diagnosed AML.
Reference Key
epemmaraju2015frontierssuccessful Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Naveen ePemmaraju;Koji eSasaki;Daniel eJohnson;Naval eDaver;Vahid eAfshar-Kharghan;Merry eChen;Sairah eAhmed;Rivka R Colen;Michael eKwon;Yang eHuh;Gautam eBorthakur
Journal international journal of heat and technology
Year 2015
DOI
10.3389/fonc.2015.00029
URL
http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00029/full
Keywords
disseminated intravascular coagulation thrombocytopenia acute myeloid leukemia Oncology including cancer and carcinogens tumors recombinant activated factor viineoplasms

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.